多发性骨髓瘤(multiple myeloma,MM)是骨髓内单克隆浆细胞恶性增殖性疾病,其发病率居血液肿瘤第2位。随着蛋白酶体抑制剂以及免疫调节剂在临床的应用,MM患者预后取得显著改善。然而,几乎所有患者仍然不可避免的出现疾病进展、复发,并且对蛋白酶体抑制剂和免疫调节剂耐药。因此,寻找具有新的作用机制的药物成为近年 Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells in bone marrow, and its incidence is the second highest in hematological malignancies. With the clinical application of proteasome inhibitors and immunomodulators, the prognosis of patients with MM has been significantly improved. However, almost all patients still inevitably have disease progression, relapse, and resistance to proteasome inhibitors and immunomodulators. Therefore, looking for drugs with a new mechanism of action has become recent years